CTOs on the Move

Areteia Therapeutics

www.areteiatx.com

 
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.areteiatx.com
  • 12770 High Bluff Drive Suite 380
    San Diego, CA USA 92130
  • Phone: 858.987.4278

Executives

Name Title Contact Details

Similar Companies

ALERT Life Sciences Computing

ALERT Life Sciences Computing is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southern Biotech Associates

Southern Biotech Associates is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AGC Biologics

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners.

http://www.katumbas.com/

http://www.katumbas.com/ is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cue Biopharma

Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.